Close
CDMO Safety Testing 2026
Novotech

Community verified biological network models show promise for toxicology and drug discovery

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.
- Advertisement -

A new set of community-produced biological network models has been shown to allow a deeper understanding of the mechanisms underlying a range of diseases.

The models, of which earlier versions have been described in detail in the past [1,2] have been shown to have important applications in toxicology and drug discovery in a new paper in Gene Regulation and Systems Biology. The models are the latest output of the Network Verification Challenge (NVC), a global crowdsourcing initiative designed to draw on expertise from many scientific areas in order to verify and enhance understanding of biological networks [3].โ€œThe Network Verification Challenge represents a powerful new approach in the identification and validation of new drug targets,โ€ said Borislav Simovic, Quality Control at FM Pharma and one of the challenge best-performers. โ€œDue to the volume of data involved, only through structured, collaborative working are we able to achieve the best understanding of biological pathways. In bringing together leading experts in toxicology and systems biology, the Network Verification Challenge gives us valuable new insights into the complex relationships involved in these pathways.โ€

ย The NVC, which is led and funded by Philip Morris International, has involved online and in-person collaborations between a global network of scientists (173 individuals from 26 countries in the latest iteration of the challenge). Networks were built using the Biological Expression Language (BEL), which captures relationships between biological entities and provides information on activation or inhibition. Applications for toxicology and drug discovery come through the overlay of data onto pathways of interest and / or the use of computational inference techniques.

The networks produced in the NVC offer a detailed and comprehensive representation of selected biological processes which is not seen in other available network resources (eg, KEGG and Reactome). NVC networks are open to the crowd for editing, which facilitates a peer-review process which helps to ensure that networks are both comprehensive and current. They also contain many layers of information with direct causal, indirect causal, correlative and other non-causal relationships being captured. The networks explored in the NVC relate to lung biology and respiratory disease, but many also apply to other tissues and disease contexts and can be built on according to scientistsโ€™ specific needs.

Participants were motivated to take part in the NVC due to the opportunity to further their understanding of the biology involved in the networks, to share their knowledge, to learn and use BEL and to collaborate with leading experts in the fields of toxicology and systems biology. Gamification principles were employed to incentivize activity on the networks, with participants able to move up a leader board based on their contributions. Best-performers had further opportunities for collaboration, including contributing to peer-reviewed papers.

โ€œAs part of the Network Verification Challenge community I have been able to contribute to state-of-the-art research in network biology,โ€ said Aravind Tallam, Postdoctoral Fellow at TWINCORE Centre for Experimental and Clinical Infection Research. โ€œAs well as improving my own understanding of disease mechanisms and underlying biology, on a personal level the challenge has also allowed me to meet and collaborate with a diverse group of scientists who are working at the cutting edge of research.โ€

The NVC is the third challenge under the sbv IMPROVER umbrella. The two previous challenges were the Diagnostic Signature Challenge, which asked participants to identify robust diagnostic signatures across four disease areas, and the Species Translation Challenge, which sought to refine understanding of the limits of rodent models as predictors of human biology. The outcomes of a fourth challenge โ€“ the Systems Toxicology Computational Challenge โ€“ were recently presented at the Intelligent Systems for Molecular Biology conference in Orlando, FL, USA. For further information about the sbv IMPROVER project, please visit http://www.sbvimprover.com.

Referencesย 

1. ย  ย  ย Boue, S. et al. Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems. Database 2015, bav030, doi:doi:10.1093/database/bav030 (2015)

2. ย  ย  ย The sbv IMPROVER project team, et al. Enhancement of COPD biological networks using a web-based collaboration interface. F1000Research 4, 32, doi:10.12688/f1000research.5984.1 (2015)

3. ย  ย  ย The sbv IMPROVER project team and NVC best performers. Community-reviewed biological network models for toxicology and drug discovery applications. Gene Regulation and Systems Biology 2016:10 1โ€“16

ย 

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.

Recombinant Proteins Driving Biologics Innovation

The landscape of modern therapeutic development is being fundamentally reshaped by the precision of recombinant proteins driving biologics innovation. These highly engineered molecules serve as the foundational architecture for initial drug discovery, the creation of sophisticated high-throughput assay development, and the eventual transition into large-scale biologics manufacturing. By utilizing advanced protein expression platforms, the pharmaceutical industry can now produce specific, high-purity proteins that effectively mimic complex natural biological functions with extraordinary accuracy, ensuring that new treatments are both safe and potent for global distribution.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป